Omega Gastric Bypass (150cm) Compared to the Roux-en-Y Gastric Bypass (YOMEGA-2 Multicentric Trial)
Study Details
Study Description
Brief Summary
Obesity with its consequences such as type 2 diabetes, high blood pressure, dyslipidemia, fatty liver disease, sleep apnea and cancers, remains a major healthcare problem worldwide. Bariatric surgery, combined with nutritional education and close monitoring, has been shown to be the most effective treatment for patients with morbid obesity resulting in significant and lasting weight loss and improvements in co-morbidities . With nearly 50000 procedures per year France ranks third in the world in terms of care for patients suffering from morbid (BMI ≥ 40 kg/m²) and severe (BMI 35-40 kg/m²) obesity.
In parallel with the significant increase in the number of patients operated on for obesity in the world, over the past two decades, significant development has been observed in the field of bariatric surgery with a decrease or even disappearance of some procedures and the appearance of others.
Performed for more than 40 years, the Roux-en-Y Gastric Bypass (RYGB) is a restrictive and malabsorptive procedure and currently is considered as gold standard procedure for the treatment of morbid obesity and its comorbidities. However, despite the good effectiveness (with an average Excess Weight Loss % (EWL%) of approximatively 70% at 2 years), RYGB is technically demanding procedure with learning curve requiring more than 100 cases and an overall complication rate ranging from 10% to 20% Introduced in 2001, one anastomosis gastric bypass (OAGB) is a modified gastric bypass that consists of a single gastrojejunal anastomosis between a long gastric pouch and a jejunal (biliopancreatic) omega loop. In Sept. 2019, taking into account the results from YOMEGA trial, the French High Authority for Health (Haute Autorité de Santé (HAS)) recommended to ban OAGB with 200 cm or longer BPL and urged to assess the efficacy and safety of OAGB with 150 cm BPL in a randomized controlled trial. Indeed, YOMEGA-2 trial is logical continuity of the YOMEGA trial.
The aim of this study is to assess weight loss efficiency and the nutritional safety of the OAGB-150 in comparison to a standard (RYGB).
The hypothesis of this study is that the OAGB with a 150 cm BPL could have the same efficacy on weight loss and nutritional complication rate in comparison to the RYGB at 2 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental group This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery. Laparoscopic OAGB will be performed with long and narrow gastric pouch (30cc) and 150 cm biliopancreatic limb |
Procedure: Laparoscopic OAGB
It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
Other Names:
|
| Active Comparator: Control Groupe This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery. Standard laparoscopic RYGB will be performed with a gastric pouch (30cc) and 150 cm antecolic Roux limb and a 50 cm biliopancreatic limb. |
Procedure: Laparoscopic RYGB
A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To demonstrate that OAGB with 150 cm biliopancreatic limb is not inferior to RYGB on weight loss (efficacy). [2 years after the surgery]
For each patient co-primary endpoints will be assessed at 2 years after surgery composed by: Efficacy: Weight loss according to Excess Weight Loss % (EWL%) calculated using the following formula: ((weight 2 years after surgery - initial weight) / (initial weight - ideal weight)) x 100. Ideal weight defined as the weight corresponding to a BMI = 25 kg/m². The assessment of the primary co-endpoint will be standardized between the sites.
- To demonstrate that OAGB with 150 cm biliopancreatic limb is not inferior to RYGB on nutritional complication rate (safety) [2 years after the surgery]
For each patient co-primary endpoints will be assessed at 2 years after surgery composed by: Safety: Nutritional complications defined by at least one vitamin deficiency (vit. B1 < 66nmol/l or B12 < 145pmol/l), malnutrition (albumin < 30g/l), anemia (hemoglobin < 10g/dl) or a combination of these. The assessment of the primary co-endpoint will be standardized between the sites.
Secondary Outcome Measures
- Measurement of albumin [Before and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of albumin will explore the nutritional status of patients. Results will be expressed in g/l
- Measurement of pre-albumin [Before and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of pre-albumin will explore the nutritional status of patients. Results will be expressed in g/l
- Measurement of hemoglobin [Before and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of hemoglobin will explore the nutritional status of patients. Results will be expressed in g/l
- Measurement of calcium [Before and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of calcium will explore the nutritional status of patients. Results will be expressed in mmol/l
- Measurement of ferritin [Before and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of ferritin will explore the nutritional status of patients. Results will be expressed in μg/l
- Measurement of iron [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of iron will explore the nutritional status of patients. Results will be expressed in mmol/l
- Measurement of % of transferrin saturation [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of % of transferrin saturation will explore the nutritional status of patients. Results will be expressed in %
- Measurement of zinc [Before surgery and 6, 12 months and 24 months after surgery]
Measurement of zinc will explore the nutritional status of patients. Results will be expressed in mmol/L
- Measurement of vitamin A [Before surgery and 6, 12 and 24 months after surgery]
Measurement of vitamin A will explore the nutritional status of patients. Results will be expressed in mmol/l
- Measurement of vitamin B1 [Before surgery and 6, 12 and 24 months after surgery]
Measurement of vitamin B1 will explore the nutritional status of patients. Results will be expressed in nmol/l
- Measurement of vitamin B9 [Before surgery and 6, 12 and 24 months after surgery]
Measurement of vitamin B9 will explore the nutritional status of patients. Results will be expressed in nmol/l
- Measurement of vitamin B12 [Before surgery and 6, 12 and 24 months after surgery]
Measurement of vitamin B12 will explore the nutritional status of patients. Results will be expressed in pmol/l
- Measurement of vitamin E [Before surgery and 6, 12 and 24 months after surgery]
Measurement of vitamin E will explore the nutritional status of patients. Results will be expressed in mmol/l
- Measurement of vitamin D [Before surgery and 6, 12 and 24 months after surgery]
Measurement of vitamin D will explore the nutritional status of patients. Results will be expressed in nmol/l
- Measurement of prothrombin rate [Before surgery and 6, 12 and 24 months after surgery]
Measurement of prothrombin rate will explore the nutritional status of patients. Results will be expressed in %
- Measurement of the 24-hour steatorrhea rate [6 month after surgery]
Measurement of the average number of stool will explore the nutritional status of patients. Results will be expressed in number of stool/day
- Measurement of HbA1c [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of HbA1c will explore the Metabolic efficiency of surgery. Results will be expressed in %
- Measurement of fasting glycemia [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of fasting glycemia will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
- Measurement of HDL [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of HDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
- Measurement of LDL [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of LDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
- Measurement of cholesterol [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of cholesterol will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
- Measurement of triglycerides [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Measurement of triglycerides will explore the Metabolic of surgery. Results will be expressed in mmol/l
- Evaluation of antidiabetic drugs [Before surgery and 6, 12 and 24 months after surgery]
Assessment of number of antidiabetic medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
- Evaluation of antilipidemic drugs [Before surgery and 6, 12 and 24 months after surgery]
Assessment of the number of antilipidemic medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment
- Evaluation of antihypertensive drugs [Before surgery and 6, 12 and 24 months after surgery]
Assessment of the number of antihypertensive medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
- Evaluation of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea [Before surgery and 6, 12 and 24 months after surgery]
Evolution of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of the use or discontinuation of the use of Continuous Positive Airway Pressure machine
- Hospitalization length [The last day of hospitalization]
The Length of stay (in days) is based on the number of days of hospitalization from surgery (day of surgery = D0) until the end of hospitalization.
- Number of patients readmitted [30 days after surgery]
Number of patients readmitted within 30 days after surgery.
- Occurrence of kidney stone [Within 2 years after surgery]
For each visit after the surgery, the presence or not of kidney stones will be documented and if applicable the treatment will be noted
- Overall complications rate [Within 24 months after surgery]
Rate of medical and surgical (> or = grade III) complications within 24 months after surgery using the Dindo-Clavien classification, described as : Grade I = Any deviation from the normal postoperative course. Grade II = Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Grade III = Requiring surgical, endoscopic or radiological intervention, not under (Grade IIIa) or under general anesthesia (Grade IIIb) Grade IV = Life-threatening complication with single organ (Grade IVa) or Multiorgan dysfunction (Grade IVb) Grade V = Death of a patient.
- Type of early complications [Within 30 days after surgery]
Type (medical or surgical) of early complications (within 30 days) for each procedure.
- Severity of early complications [Within 30 days after surgery]
Severity of early complications (within 30 days) for each procedure according to the Dindo-Clavien classification
- Type of late complications [Within 2 years after surgery]
Type (medical or surgical) of late complications (after 30 days) for each procedure.
- Severity of late complications [Within 2 years after surgery]
Severity of late complications (after 30 days) for each procedure according to the Dindo-Clavien classification
- Gastroesophageal reflux assessment [Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery]
Evolution of gastroesophageal reflux will be assessed at each study visit, before and after surgery. This outcome will be expressed in terms of improvement, aggravation or onset.
- Absolute weight loss assessment [1, 3, 6, 12, 18 and 24 months after surgery]
Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according to absolute weight loss (aWL) in kg.
- Excess Weight Loss percentage assessment [1, 3, 6, 12, 18 and 24 months after surgery]
Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according to Excess Weight Loss percentage (EWL%), calculated using the following formula: ((weight at visit X - initial weight) / (initial weight - ideal weight)) X 100
- Excess BMI Loss percentage assessment [1, 3, 6, 12, 18 and 24 months after surgery]
Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according Excess BMI Loss percentage (EBL%), according to the formula : ((BMI at visit X - initial BMI) / (initial BMI - ideal BMI)) X 100 with Ideal BMI = 25 kg/m²
- Quality of life assessed with GIQLI questionnaire [Before surgery and at 6, 12 and 24 months after surgery]
This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to the patients and for each answer, a score ranging from 0 to 4 (highest score = 144) will be assigned. A high score defines a more favorable health state
- Quality of life assessed with SF36 questionnaire [Before surgery and at 6, 12 and 24 months after surgery]
This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/tiredness, and general health perceptions. It also includes a single item that provides an indication of a perceived change in health
- Quality of life assessed with Sigstad questionnaire [Before surgery and at 1, 3, 6, 12, 18 and 24 months after surgery]
The Sigstad questionnaire allows the identification and diagnosis of postoperative dumping syndrome and early hypoglycaemia: a score >7 suggests a dumping syndrome
- Body composition [Before and 24 months after surgery.]
Body composition level on a subsample of the total population: By impedancemetry : Muscle mass index in kg/m2 Non-fat mass index in kg/m2 Fat mass index in kg/m2
- Sarcopenia level [Before and 24 months after surgery.]
Sarcopenia level on a subsample of the total population will be assessed by Handgrip Strength
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient aged from 18 to 65 years old
-
Type III obesity (BMI ≥ 40 kg/m²), or Type II obesity BMI 35-40 kg/m2 associated with at least one co-morbidity which will be improved by surgery (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis)
-
Patient who had benefited from an Upper GI Endoscopy with biopsies to look for Helicobacter pylori within 12 months before surgery
-
Patient who has benefited from a multidisciplinary evaluation at least 6 months, with a favorable opinion for a gastric bypass
-
Patient who understood and accepted the need for a long-term follow-up
-
Patient who agreed to be included in the study and who signed the informed consent form
-
Patient affiliated to a social security scheme
-
For child-bearing aged women, efficient contraception
Exclusion Criteria:
-
History of previous bariatric surgery
-
History of chronic inflammatory bowel disease
-
Presence of chronic diarrhea
-
Presence of a severe and evolutive life threatening pathology
-
Presence of dysplastic modifications of the gastric mucosa, chronic atrophic gastritis or history of gastric cancer
-
Presence of an unhealed gastro-duodenal ulcer
-
Presence of Helicobacter pylori resistant to medical treatment
-
Presence of esophagitis
-
Pregnancy or desire to be pregnant during the study
-
Mentally unbalanced patients, under supervision or guardianship
-
Patients who don't understand French and not able to give consent
-
Patient included and followed in another interventional trial
-
Unable to consent, under tutelage or curatorship, or judiciary safeguard
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Bichat Claude-Bernard | Paris | France |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Tigran POGHOSYAN, MD-PhD, Bichat (APHP)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP 211050